VRTX - Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players
Vertex (VRTX), the inventor of the new cystic fibrosis wonder drug Trikafta, is a shining star amongst biotech and pharmaceuticals for 2020. On a background of strong fundamentals, with forecasted EBITDA growth of 51.29% in the coming year just to name a few, investors have demonstrated an expectation of extraordinary results into the coming periods. Thus, a compelling investment case is made for medium-term players to capture fantastic returns over the next multiple periods, which is summarised below.
Profitability
The company has delivered CAGR revenue of 33.65% over the previous 3 years and